Qiming Venture Partners (启明创投)

Plus: Ark, Atom file for Hong Kong listings; PIPEs for Sichuan Biokin, Oruka; Langer-backed fund T.Rx; rounds for Lila, Ollin, AllRock, Dualitas and more

Launching with $65M series A, Bay Area biotech aims to discover new target combinations for I&I bispecifics

Plus: Venture rounds for NRG, Epigenic, Ridge and more

Plus: Public raises for Assembly, Sana and Shattuck

Plus: Nisa Leung leaves Qiming, and updates from Northsea, Ventus, Arima and Gate

Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global

In BioCentury’s latest Venture Report, two trans-Pacific companies and a gene therapy newco draw funding

Deal-making with the West offers a path through uncertain times, but in what position will China biotechs emerge from the bear?

Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G

Ken Song’s post-RayzeBio venture pulled together two licensing deals, an M&A transaction and three financings totaling $370M